IRIS
SCARFO', LYDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.345
EU - Europa 3.281
NA - Nord America 3.138
SA - Sud America 893
AF - Africa 56
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.732
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.036
RU - Federazione Russa 1.940
SG - Singapore 1.212
CN - Cina 1.030
BR - Brasile 735
HK - Hong Kong 540
SE - Svezia 338
IT - Italia 278
VN - Vietnam 271
DE - Germania 169
FR - Francia 165
GB - Regno Unito 90
AR - Argentina 71
FI - Finlandia 63
IN - India 57
CA - Canada 41
MX - Messico 41
AT - Austria 38
IQ - Iraq 33
EC - Ecuador 32
PL - Polonia 32
BD - Bangladesh 30
NL - Olanda 29
ID - Indonesia 28
ES - Italia 26
JP - Giappone 25
IE - Irlanda 23
GR - Grecia 21
CO - Colombia 19
AU - Australia 18
ZA - Sudafrica 18
BE - Belgio 16
PK - Pakistan 15
TR - Turchia 15
UA - Ucraina 14
VE - Venezuela 14
AE - Emirati Arabi Uniti 13
PY - Paraguay 12
SA - Arabia Saudita 10
IL - Israele 9
TN - Tunisia 9
LT - Lituania 7
MA - Marocco 7
UZ - Uzbekistan 7
KE - Kenya 6
MY - Malesia 6
NO - Norvegia 6
ET - Etiopia 5
JO - Giordania 5
BB - Barbados 4
BH - Bahrain 4
KZ - Kazakistan 4
LU - Lussemburgo 4
NP - Nepal 4
PA - Panama 4
PH - Filippine 4
AL - Albania 3
AZ - Azerbaigian 3
CH - Svizzera 3
CL - Cile 3
DK - Danimarca 3
EG - Egitto 3
KR - Corea 3
LB - Libano 3
LV - Lettonia 3
PE - Perù 3
SN - Senegal 3
UY - Uruguay 3
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
IR - Iran 2
JM - Giamaica 2
RS - Serbia 2
TW - Taiwan 2
AI - Anguilla 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
DZ - Algeria 1
GD - Grenada 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LS - Lesotho 1
LY - Libia 1
ML - Mali 1
NA - Namibia 1
OM - Oman 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
Totale 10.729
Salva come PNG Salva come JPEG
Città #
Dallas 1.388
Singapore 632
Hong Kong 537
Moscow 447
Ashburn 359
San Jose 225
Shanghai 225
Hefei 149
Beijing 143
Lauterbourg 127
New York 105
Lawrence 97
Princeton 97
Ho Chi Minh City 92
Milan 82
Hanoi 57
Los Angeles 57
Nuremberg 56
São Paulo 54
Munich 44
Boardman 40
Warsaw 29
Rome 27
Helsinki 24
Dublin 23
Tokyo 23
Chennai 21
Orem 20
Rio de Janeiro 20
Turku 20
Da Nang 19
Guangzhou 19
Vienna 19
Council Bluffs 18
Denver 18
Houston 18
Montreal 17
Poplar 17
Thessaloniki 17
Boston 16
Brooklyn 16
Hangzhou 15
Santa Clara 15
Brasília 14
Frankfurt am Main 14
Lappeenranta 14
Manchester 13
Phoenix 13
Buffalo 12
Johannesburg 12
Porto Alegre 12
Stockholm 12
Atlanta 11
Baghdad 11
Belo Horizonte 11
London 11
Brussels 10
Chicago 10
Columbus 10
Curitiba 10
Monza 10
Querétaro 10
Shenzhen 10
Amsterdam 9
Guarulhos 9
Mexico City 9
Quito 9
Ribeirão Preto 9
Toronto 9
Asunción 8
Biên Hòa 8
Dubai 8
Haiphong 8
Oviedo 8
The Dalles 8
Wuxi 8
Florianópolis 7
Guayaquil 7
Jakarta 7
Mumbai 7
Naples 7
Ninh Bình 7
San Francisco 7
Zhengzhou 7
Bari 6
Buenos Aires 6
Cleveland 6
Dhaka 6
Goiânia 6
Istanbul 6
Jiaxing 6
Manaus 6
Medellín 6
Mol 6
Nairobi 6
Seattle 6
Sydney 6
Tashkent 6
Wollongong 6
Addis Ababa 5
Totale 5.935
Salva come PNG Salva come JPEG
Nome #
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 424
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 419
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 408
Exploring Perceptions, Opinions, and Needs of Adult and Pediatric Cancer Patients, Caregivers, and Healthcare Professionals Towards Low-Fidelity Versions of the MyPal Project's Applications: Findings from 12 Pre-Pilot Focus Groups in 4 European Countries of an ePRO Intervention for Palliative Cancer Care (Preprint) 191
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 142
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 138
Chronic lymphocytic leukaemia 129
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 122
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 112
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 110
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 106
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 106
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 101
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 97
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 95
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 94
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 93
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 93
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 91
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 90
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 90
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 89
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 89
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 87
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 87
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 86
Targeting B-cell anergy in chronic lymphocytic leukemia. 86
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 86
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 85
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 85
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 84
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 83
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 83
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 82
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 81
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 81
3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells 81
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 80
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 79
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 77
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 77
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 77
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 74
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 74
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 74
CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? 72
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience 72
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 71
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 71
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 71
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 71
Monoclonal B lymphocytosis in the general population 70
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. 70
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients 70
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 69
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 68
Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia 68
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 67
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 67
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 66
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia 66
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia 66
Profiling the Genomic Landscape at the Early Stages of CLL: Low Genomic Complexity and Paucity of Driver Mutations in MBL and Indolent CLL 66
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 65
Loss of CYLD promotes splenic marginal zone lymphoma 65
Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia 65
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 65
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 64
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia 64
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY 63
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 63
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 62
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL 62
Monoclonal B Cell Lymphocytosis in Hepatitis C Virus Infected Individuals 62
Infrequent "chronic lymphocytic leukemia-specific" immunoglobulin stereotypes in aged individuals with or without low count monoclonal B cell lymphocytosis 62
MyPal-Child study protocol: An observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients 62
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study 61
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 61
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 60
Co-Designing Smartphone Notifications According to the Clinical Routine of Cancer Patients 60
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 60
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment 60
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities 60
Relevance of Minimal Residual Disease in the Era of Targeted Agents 60
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors 57
Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia 57
Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control 57
MyPal ADULT study protocol: A randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies 57
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy 57
Highly similar genomic landscapes in monoclonal b-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations 56
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line 56
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 55
Single cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib 55
Fostering Palliative Care Through Digital Intervention: A Platform for Adult Patients With Hematologic Malignancies 54
Prognostic relevance of MYD88 mutations in CLL: the jury is still out 54
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 54
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy 54
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 54
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia 53
Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Time to Retire? 53
Totale 8.648
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.196
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202275 0 0 0 21 6 3 8 19 7 6 2 3
2022/2023616 215 113 54 1 16 82 23 34 40 8 11 19
2023/2024477 13 20 27 119 22 71 4 27 1 12 44 117
2024/20252.285 276 53 63 60 87 164 243 215 393 340 182 209
2025/20267.462 544 1.018 1.057 992 542 191 555 487 1.798 278 0 0
Totale 11.009